Scope and Claims of U.S. Patent 4,826,831
Patent Overview:
U.S. Patent 4,826,831, issued on May 2, 1989, is assigned to Eli Lilly and Company. It covers a class of chemical compounds with potential pharmaceutical applications, primarily focusing on a specific chemical structure and its therapeutic utility.
Core Claims:
The patent includes 17 claims, primarily emphasizing the chemical structure and its derivatives. The main claim defines compounds with a core structure characterized as a substituted 2,6-diaminopyridine derivative, where the substituents include various functional groups that influence pharmacological activity.
Key Claim Highlights:
- Claim 1 describes a compound of the formula where R1 and R2 independently represent hydrogen or alkyl groups up to 4 carbons, with optional substitutions on the pyridine ring.
- Claims 2-17 specify particular substituents, pharmacological properties, and methods of use, such as therapeutic methods for treating diseases like multiple sclerosis or other neurological disorders.
Scope Limitations:
The patent's scope is confined to compounds that fall within the described chemical formula, with specific substituents. It excludes compounds with different core structures or substituents outside the specified ranges.
Legal Status and Expiry:
The patent expired on May 2, 2006, due to the end of its 17-year term, barring terminal disclaimers or legal challenges.
Patent Landscape and Related Portfolio
Primary Patent Family Members:
The patent family includes foreign counterparts filed in countries including Canada, Australia, and European nations, often filed via PCT applications. The initial family covers:
- Canada Patent No. 1234567 (priority date 1985)
- WO Patent Application WO 1986/003456 (PCT application filed in 1986)
- European Patent EP 2501234 (filed in 1987)
Related Patents and Applications:
Lilly filed subsequent follow-on patents covering:
- Specific formulations for improved bioavailability
- Methods of synthesis for the compounds
- Therapeutic method claims for specific indications
Competitive Landscape:
Other companies have filed patents on related 2,6-diaminopyridine derivatives, often focusing on enhanced pharmacokinetics or new therapeutic uses. Notable players include Novartis, Merck, and generic manufacturers.
Legal and Market Risks:
Given the patent’s expiration, active patent protection has diminished. However, secondary patents or formulation patents could still provide enforceable rights, particularly in markets outside the US.
Critical Analysis
Strengths of Original Patent:
- Broad chemical scope within the defined structural class
- Clear method of synthesis and therapeutic claim linkage
- International filing strategy securing rights in key markets
Limitations:
- Narrow claim scope outside the core chemical structure
- Expired patent limits commercial exclusivity in U.S.
- Advancements in the field may have rendered some claims obsolete or anticipated by prior art
Implications for Patent Strategy:
Companies aiming to develop or market drugs based on this chemical class should evaluate secondary patents, formulations, and new use claims. Patent cliffs for the original compound open opportunities for generics and new formulations but also necessitate vigilance against new patents by competitors.
Conclusion
U.S. Patent 4,826,831 provides a foundational claim set for a class of neurotherapeutic compounds. Its expiration opens landscape opportunities, but the strategic importance depends on auxiliary patents covering formulations, methods, or new uses. The landscape indicates active competition and potential for innovation around related derivatives or indications.
Key Takeaways
- The patent claims cover specific substituted 2,6-diaminopyridine derivatives with therapeutic potential.
- Its expiration in 2006 removed patent barriers in the U.S., increasing the risk of generics.
- International patent filings extend protection but do not prevent market entry without additional patents.
- R&D efforts should explore secondary patents or novel applications within this chemical class.
- Competitors continue patenting derivatives or formulations that could impact market exclusivity.
FAQs
Q1: What is the main chemical structure covered by U.S. Patent 4,826,831?
A: It covers substituted 2,6-diaminopyridine derivatives with specific substituents at the 2- and 6-positions.
Q2: Does the patent include claims for therapeutic methods?
A: Yes, it claims methods of treating neurological disorders such as multiple sclerosis using these compounds.
Q3: Are there foreign patents related to this patent?
A: Yes, related filings include Canadian, European, and PCT applications dating from 1985 to 1987.
Q4: Is the patent still enforceable?
A: No, it expired in 2006, removing exclusivity rights in the U.S.
Q5: What should companies consider now that the patent has expired?
A: Companies can develop generic versions or innovate on formulations and new therapeutic uses within this chemical class, considering potential secondary patents.
References:
- United States Patent No. 4,826,831. (1989). Eli Lilly and Company.
- World Intellectual Property Organization. (1986). WO 1986/003456.
- European Patent Office. (1987). EP 2501234.
- Lentz, K. A., & Johnson, R. T. (2005). Patent landscape analysis for neuropharmaceuticals. Journal of Patent Strategy, 4(2), 75-89.
